Linked Life Data

18759698

Source:http://linkedlifedata.com/resource/pubmed/id/18759698

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2008-9-1
pubmed:abstractText
Over the past 10 years, healthcare providers involved in the management of metastatic colorectal cancer (MCRC) have seen an explosion in new agents and their combinations. These developments have resulted in an expansion in the options of care for MCRC patients and in a significant improvement in their overall survival. This article reviews the current role of anti-EGFR monoclonal antibodies in the management of MCRC and the identification of recent markers of response that lead towards treatment individualization.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1744-8328
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1471-80
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
pubmed:affiliation
Roswell Park Cancer Institute, Buffalo, NY 14263, USA. marwan.fakih@roswellpark.org
pubmed:publicationType
Journal Article, Review